Drug Profile

Omalizumab biosimilar - GENERIUM Pharmaceuticals

Alternative Names: Genolair; GNR-044

Latest Information Update: 18 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GENERIUM Pharmaceuticals
Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action IgE receptor antagonists; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Asthma; Chronic urticaria
Phase I Allergic asthma

Most Recent Events

09 Jun 2024 GENERIUM Pharmaceuticals completes a phase I trial in Allergic asthma in Russia (SC, Solution/Wafer) (NCT06494345)
31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
09 Feb 2022 GENERIUM Pharmaceuticals in-licenses SUREtechnology Platform™ from Selexis prior to February 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com